Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab

Mohd Wahid, Naseem Akhter, Arshad Jawed, Sajad A. Dar, Raju K. Mandal, Mohtashim Lohani, Mohammed Y. Areeshi, Saif Khan, Shafiul Haque

Research output: Contribution to journalReview ArticleScientificpeer-review

Original languageEnglish
JournalCritical Reviews in Oncology / Hematology
Volume111
Pages (from-to)1-6
Number of pages6
ISSN1040-8428
DOIs
Publication statusPublished - Mar 2017
MoE publication typeA2 Review article in a scientific journal

Fields of Science

  • Metastatic skin cancer
  • Programmed cell death-1
  • Non-cross resistant
  • BRAF inhibitors
  • Ipilimumab
  • Pembrolizumab
  • T-CELL-ACTIVATION
  • MONOCLONAL-ANTIBODIES
  • ADVANCED MELANOMA
  • CTLA-4
  • CANCER
  • 3121 Internal medicine
  • 3122 Cancers

Cite this

Wahid, Mohd ; Akhter, Naseem ; Jawed, Arshad ; Dar, Sajad A. ; Mandal, Raju K. ; Lohani, Mohtashim ; Areeshi, Mohammed Y. ; Khan, Saif ; Haque, Shafiul. / Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab. In: Critical Reviews in Oncology / Hematology. 2017 ; Vol. 111. pp. 1-6.
@article{6794dac493414b1aa05b6d7749417113,
title = "Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab",
keywords = "Metastatic skin cancer, Programmed cell death-1, Non-cross resistant, BRAF inhibitors, Ipilimumab, Pembrolizumab, T-CELL-ACTIVATION, MONOCLONAL-ANTIBODIES, ADVANCED MELANOMA, CTLA-4, CANCER, 3121 Internal medicine, 3122 Cancers",
author = "Mohd Wahid and Naseem Akhter and Arshad Jawed and Dar, {Sajad A.} and Mandal, {Raju K.} and Mohtashim Lohani and Areeshi, {Mohammed Y.} and Saif Khan and Shafiul Haque",
year = "2017",
month = "3",
doi = "10.1016/j.critrevonc.2017.01.001",
language = "English",
volume = "111",
pages = "1--6",
journal = "Critical Reviews in Oncology / Hematology",
issn = "1040-8428",
publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",

}

Wahid, M, Akhter, N, Jawed, A, Dar, SA, Mandal, RK, Lohani, M, Areeshi, MY, Khan, S & Haque, S 2017, 'Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab' Critical Reviews in Oncology / Hematology, vol. 111, pp. 1-6. https://doi.org/10.1016/j.critrevonc.2017.01.001

Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab. / Wahid, Mohd; Akhter, Naseem; Jawed, Arshad; Dar, Sajad A.; Mandal, Raju K.; Lohani, Mohtashim; Areeshi, Mohammed Y.; Khan, Saif; Haque, Shafiul.

In: Critical Reviews in Oncology / Hematology, Vol. 111, 03.2017, p. 1-6.

Research output: Contribution to journalReview ArticleScientificpeer-review

TY - JOUR

T1 - Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab

AU - Wahid, Mohd

AU - Akhter, Naseem

AU - Jawed, Arshad

AU - Dar, Sajad A.

AU - Mandal, Raju K.

AU - Lohani, Mohtashim

AU - Areeshi, Mohammed Y.

AU - Khan, Saif

AU - Haque, Shafiul

PY - 2017/3

Y1 - 2017/3

KW - Metastatic skin cancer

KW - Programmed cell death-1

KW - Non-cross resistant

KW - BRAF inhibitors

KW - Ipilimumab

KW - Pembrolizumab

KW - T-CELL-ACTIVATION

KW - MONOCLONAL-ANTIBODIES

KW - ADVANCED MELANOMA

KW - CTLA-4

KW - CANCER

KW - 3121 Internal medicine

KW - 3122 Cancers

U2 - 10.1016/j.critrevonc.2017.01.001

DO - 10.1016/j.critrevonc.2017.01.001

M3 - Review Article

VL - 111

SP - 1

EP - 6

JO - Critical Reviews in Oncology / Hematology

JF - Critical Reviews in Oncology / Hematology

SN - 1040-8428

ER -